Table 1 Baseline characteristics of patients who underwent adjuvant therapy for stage IIB or III according to the presence of clonal hematopoiesis (final cohort)
Variables | Total (n = 415) | CH ( +) (n = 86) | CH ( −) (n = 329) | p-value |
|---|---|---|---|---|
Age (year) | 60.2 ± 8.3 | 63.0 ± 8.2 | 59.5 ± 8.2 | 0.001* |
Sex (male) | 270 (65.1) | 60 (69.8) | 210 (63.8) | 0.367 |
History of smoking | 248 (59.8) | 53 (61.6) | 195 (59.3) | 0.785 |
The number of comorbidities | 0.988 | |||
0 | 225 (54.2) | 46 (53.5) | 179 (54.4) | |
1 | 123 (29.6) | 26 (30.2) | 97 (29.5) | |
≥ 2 | 67 (16.1) | 14 (16.3) | 53 (16.1) | |
Pulmonary function | ||||
FEV1 < 60% | 17 (4.1) | 4 (4.7) | 13 (4.0) | 1.000 |
DLCO < 60% | 25 (6.0) | 6 (7.0) | 19 (5.8) | 0.871 |
Histologic structure | 0.647 | |||
ADC* | 54 (62.8) | 220 (66.9) | ||
SqCC* | 24 (27.9) | 87 (26.4) | ||
Others | 8 (9.3) | 22 (6.7) | ||
Maximal tumor size (mm) | 40.6 ± 17.6 | 40.6 ± 17.3 | 40.6 ± 17.7 | 0.997 |
EGFR mutation | 0.501 | |||
Yes | 110 (26.5) | 22 (25.6) | 88 (26.7) | |
No | 124 (29.9) | 22 (25.6) | 102 (31.0) | |
Unchecked | 181 (43.6) | 42 (48.8) | 139 (42.2) | |
Pathological T factor | 0.280 | |||
T1 | 81 (19.5) | 22 (25.6) | 59 (17.9) | |
T2 | 186 (44.8) | 32 (37.2) | 154 (46.8) | |
T3 | 110 (26.5) | 25 (29.1) | 85 (25.8) | |
T4 | 38 (9.2) | 7 (8.1) | 31 (9.4) | |
Pathological N factor | 0.791 | |||
N0 | 43 (10.4) | 9 (10.5) | 34 (10.3) | |
N1 | 182 (43.9) | 35 (40.7) | 147 (44.7) | |
N2 | 190 (45.8) | 42 (48.8) | 148 (45.0) | |
Pathological stage | 0.548 | |||
IIB | 170 (41.0) | 31 (36.0) | 139 (42.2) | |
IIIA | 192 (46.3) | 44 (51.2) | 148 (45.0) | |
IIIB | 53 (12.8) | 11 (12.8) | 42 (12.8) | |
Type of adjuvant therapy | 0.146 | |||
CTx | 248 (59.8) | 45 (52.3) | 203 (61.7) | |
CRTx | 167 (40.2) | 41 (47.7) | 126 (38.3) | |